This old version of Proteopedia is provided for student assignments while the new version is undergoing repairs. Content and edits done in this old version of Proteopedia after March 1, 2026 will eventually be lost when it is retired in about June of 2026.
Apply for new accounts at the new Proteopedia. Your logins will work in both the old and new versions.
1pvg
From Proteopedia
|
Crystal Structure of the ATPase region of Saccharomyces Cerevisiae topoisomerase II
Overview
Type IIA topoisomerases both manage the topological state of chromosomal, DNA and are the targets of a variety of clinical agents., Bisdioxopiperazines are anticancer agents that associate with ATP-bound, eukaryotic topoisomerase II (topo II) and convert the enzyme into an, inactive, salt-stable clamp around DNA. To better understand both topo II, and bisdioxopiperazine function, we determined the structures of the, adenosine 5'-[beta,gamma-imino]-triphosphate-bound yeast topo II ATPase, region (ScT2-ATPase) alone and complexed with the bisdioxopiperazine, ICRF-187. The drug-free form of the protein is similar in overall fold to, the equivalent region of bacterial gyrase but unexpectedly displays, significant conformational differences. The ternary drug-bound complex, reveals that ICRF-187 acts by an unusual mechanism of inhibition in which, the drug does not compete for the ATP-binding pocket, but bridges and, stabilizes a transient dimer interface between two ATPase protomers. Our, data explain why bisdioxopiperazines target ATP-bound topo II, provide a, structural rationale for the effects of certain drug-resistance mutations, and point to regions of bisdioxopiperazines that might be modified to, improve or alter drug specificity.
About this Structure
1PVG is a Single protein structure of sequence from Saccharomyces cerevisiae with MG and ANP as ligands. Active as DNA topoisomerase (ATP-hydrolyzing), with EC number 5.99.1.3 Full crystallographic information is available from OCA.
Reference
Structure of the topoisomerase II ATPase region and its mechanism of inhibition by the chemotherapeutic agent ICRF-187., Classen S, Olland S, Berger JM, Proc Natl Acad Sci U S A. 2003 Sep 16;100(19):10629-34. Epub 2003 Sep 8. PMID:12963818
Page seeded by OCA on Wed Nov 21 00:09:26 2007
